⌕
Novavax · NVAX · Nasdaq
Tenet 37 · Weak
Compare
$8.06−5.45%At closeTenet 37 · Weak
$8.06−0.47 (−5.45%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Novavax (NVAX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 43% below its peak, net margin 39.2%; free cash flow runs at −57% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+132.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲64.7%
1,123.5
FY21→FY25CAGR −0.5%/yr
Net income ($M)—
440.3
FY21→FY25CAGR —
Free cash flow ($M)▼146.3%
−251.0
FY21→FY25CAGR —
Diluted EPS—
2.58
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+132.7%

74.4mn → 173.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$6.4M

−56.4% YoY in FY25 · 0.6% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1123.5Revenue−73.0COGS−342.3R&D−157.5SG&A452.8Op income−12.5Tax & other440.3Net income

39¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Net margin 39.2% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
411.61,123.5682.2983.71,981.91,146.3▲64.7%−0.5%
Cost of revenue
90.573.0202.7343.8902.60.0▼64.0%−56.7% (22→25)
Gross profit
321.1—A479.4639.91,079.21,146.3——
Research & development
294.5342.3391.2737.51,235.32,534.5▼12.5%−39.4%
Selling, general & admin
113.2157.5337.2468.9488.7298.4▼53.3%−14.8%
Total operating expenses
408.5597.6728.41,206.41,724.02,832.9▼17.9%−32.2%
Operating incomefeeds ROC rank
−87.4452.8−248.9−566.5−644.7−1,686.6——
Other income, net
15.5−10.672.323.5−8.9−28.0——
Pretax income
−71.9442.2−176.6−543.0−653.6−1,714.5——
Income tax
4.81.910.92.04.329.2▼82.9%−49.7%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
−76.7440.3−187.5−545.1−657.9−1,743.8——
Per share
Diluted EPSbuyback-sensitive
−0.292.58−1.23−5.41−8.42−23.44——
Diluted shares (mn)
164.92173.10152.19100.7778.1874.40▲13.7%+23.5%
Margins
Gross margin71st pct in Healthcare
78.0%—A70.3%65.1%54.5%100.0%——
Operating margin
−21.2%40.3%−36.5%−57.6%−32.5%−147.1%▲76.8pp+187.4pp
Net margin23rd pct in Healthcare
−18.6%39.2%−27.5%−55.4%−33.2%−152.1%▲66.7pp+191.3pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Novavax's revenue last fiscal year?

Novavax reported revenue of $1,123.5M in fiscal 2025, up 64.7% from fiscal 2024.

What was Novavax's net income?

Novavax reported net income of $440.3M in fiscal 2025, a net margin of 39.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.